Opinion

Video

Rectal Separation for Prostate Cancer Radiation Therapy: Clinical Data on Barrigel and BioProtect

Author(s):

Daniel Allan Hamstra, MD, PhD, FASTRO, FASCO

The Phase 3 trials for the Barrigel and BioProtect rectal spacers demonstrated a dosimetric advantage and reduced rectal toxicity similar to SpaceOAR, but data on long-term toxicity and patient-reported outcomes is still needed to fully evaluate the newer spacers.

Related Videos
Alexander Pastuszak, MD, PhD: Is hormone therapy safe after prostate cancer radiotherapy?
Refining prostate cancer therapy strategy to address RAPTOR findings
Soumyajit Roy, MS, MBBS: The effect of prostate cancer patient history in RAPTOR
1 KOL is featured in this series.
1 KOL is featured in this series.
Nicholas van AS, MD, MBBCH: The case for SBRT as a standard of care for localized prostate cancer
Pierre Blanchard, MD, PhD: What can hydrogel space provide to optimal prostate cancer care?
Savita Dandapani, MD, PhD: Findings from the phase 2 SHARP trial
A panel of 4 experts on prostate cancer
Benjamin Pockros, MD, MBA, answers a question during a Zoom video interview
Related Content
Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC
October 2nd 2024

Apalutamide associated with improved 2-year survival vs enzalutamide in mCSPC

Hannah Clarke
At the 24-month time point, patients who received apalutamide had a 23% reduction in the risk of death compared with patients who initiated enzalutamide.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Short-term ADT plus radiotherapy improves disease-free survival in higher-risk prostate cancer
September 30th 2024

Short-term ADT plus radiotherapy improves disease-free survival in higher-risk prostate cancer

Kevin Kunzmann
Findings from GETUG 14 show short-term ADT with high-dose radiotherapy provided 5-year improved efficacy without increased risk of toxicity.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
Prior local therapy does not impact mCRPC survival with ARPI treatment
September 29th 2024

Prior local therapy does not impact mCRPC survival with ARPI treatment

Kevin Kunzmann
A late-breaking abstract at ASTRO 2024 shows local therapy history does not significantly affect the risk of death in patients with mCRPC receiving an ARPI.
How do prostate cancer treatments differ in longterm functional outcomes?
September 28th 2024

How do prostate cancer treatments differ in longterm functional outcomes?

Kevin Kunzmann
New CEASAR findings at ASTRO 2024 show how 3 treatment modalities differ in prostate cancer patient functioning—as well as how patients perceive the issues.
© 2024 MJH Life Sciences

All rights reserved.